• Patients who were most non-adherent were those who were <60 years old, black, treated with protease inhibitors and drug abusers.
PREDICTING HUMAN IMMUNODEFICIENCY VIRUS VETERANS' ADHERENCE TO ANTIRETROVIRAL AGENTS VIA OPTIMAL DATA ANALYSIS
• Adherence was dichotomized at different threshold of 75%, 80%, 85%, 90% and 95%.
• Candidate predictors: 1) demographic variables for age, race/ethnicity, marital status, and gender; 2) various classifications of disease characteristics such as HAART regimen, CD4 count, and HIV RNA viral load; and 3) dichotomous comorbidity classifications. The Charlson comorbidity index was also used.
Analysis
• ODA paradigm:
• A hierarchical decision tree was built to predict patient adherence at different adherence thresholds.
• Three rules were applied to pick the predictors: 1) at each decision point, the predictor with the lowest Fisher's exact p-value was selected; 2) leave-one-out jackknife analysis was performed to select a stable predictor; and 3) dividing a branch of the decision tree was stopped if the branch had less than 15 patients.
Abstract
OBJECTIVES: Human immunodeficiency virus (HIV) treatment guidelines recommend target adherence levels of 95% and suggest that treatment be postponed in patients at risk of poor adherence. Little objective guidance is provided to clinicians for identifying such patients. We applied an optimal data analysis (ODA) paradigm to create predictive models for adherence in a national cohort of United States veterans using electronic medical records (EMRs) by maximizing predictive accuracy.
METHODS:
Quarterly adherence to antiretroviral agents was calculated as the proportion of days covered (PDC) with 3 or more antiretroviral agents from 2 or more drug classes. A hierarchical decision tree was built to predict patient adherence at different adherence thresholds of 75%, 80%, 85%, 90% and 95%. The attribute variables included demographics, comorbidities, and disease characteristics. Three rules were applied to pick the predictors: 1) at each decision point, the attribute with the lowest Fisher's exact p-value was selected; 2) leave-one-out jackknife analysis was performed to select a stable attribute; and 3) dividing a branch of decision tree was stopped if the branch had less than 15 patients.
RESULTS:
3864 HIV patients newly initiated highly active antiretroviral therapy in 1998-2006. The mean age of the cohort was 56.3±9.4 years old and 98.4% were males. The mean (95% CI) PDC in quarter 1 was 20.9% (41.6-45.0%) and reached a maximum of 43.3% (20.2-21.7%) in quarter 26. The ODA models for different thresholds predicted adherence with a C-statistic of 0.58-0.63, a range of accuracy defined as no discrimination to poor discrimination. Patients who were most nonadherent were those who were <60 years old, black, treated with protease inhibitors and drug abusers.
CONCLUSIONS:
Using discrete data in the EMRs, it is difficult to predict patients at risk of poor adherence. Future work should include more complex predictors such as patient adherence to other therapies. Figure : ODA model for adherence at 95% threshold 
